These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27370606)

  • 1. New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints.
    Wang VE; Grandis JR; Ko AH
    Clin Cancer Res; 2016 Sep; 22(17):4283-90. PubMed ID: 27370606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities.
    Cousin S; Italiano A
    Clin Cancer Res; 2016 Sep; 22(18):4550-5. PubMed ID: 27435397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
    Wu X; Giobbie-Hurder A; Liao X; Connelly C; Connolly EM; Li J; Manos MP; Lawrence D; McDermott D; Severgnini M; Zhou J; Gjini E; Lako A; Lipschitz M; Pak CJ; Abdelrahman S; Rodig S; Hodi FS
    Cancer Immunol Res; 2017 Jan; 5(1):17-28. PubMed ID: 28003187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy in esophageal cancer.
    Zhang L; Ma J; Han Y; Liu J; Zhou W; Hong L; Fan D
    Expert Rev Gastroenterol Hepatol; 2016; 10(5):595-604. PubMed ID: 26895097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery.
    Mosely SI; Prime JE; Sainson RC; Koopmann JO; Wang DY; Greenawalt DM; Ahdesmaki MJ; Leyland R; Mullins S; Pacelli L; Marcus D; Anderton J; Watkins A; Coates Ulrichsen J; Brohawn P; Higgs BW; McCourt M; Jones H; Harper JA; Morrow M; Valge-Archer V; Stewart R; Dovedi SJ; Wilkinson RW
    Cancer Immunol Res; 2017 Jan; 5(1):29-41. PubMed ID: 27923825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired resistance to cancer immunotherapy.
    Draghi A; Chamberlain CA; Furness A; Donia M
    Semin Immunopathol; 2019 Jan; 41(1):31-40. PubMed ID: 29968044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in targeted therapy for esophageal cancer.
    Yang YM; Hong P; Xu WW; He QY; Li B
    Signal Transduct Target Ther; 2020 Oct; 5(1):229. PubMed ID: 33028804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy for advanced esophagogastric adenocarcinoma.
    Kordes S; Cats A; Meijer SL; van Laarhoven HW
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):68-76. PubMed ID: 24183912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational Landscape and Sensitivity to Immune Checkpoint Blockers.
    Chabanon RM; Pedrero M; Lefebvre C; Marabelle A; Soria JC; Postel-Vinay S
    Clin Cancer Res; 2016 Sep; 22(17):4309-21. PubMed ID: 27390348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemokines and cancer: new immune checkpoints for cancer therapy.
    Karin N
    Curr Opin Immunol; 2018 Apr; 51():140-145. PubMed ID: 29579623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effect of immune-based therapy with cytotoxic T lymphocyte and molecular targeting therapy for HER2 in esophageal squamous cell carcinoma].
    Mimura K; Izawa S; Siba S; Maruyama T; Watanabe M; Kawaguchi Y; Fuji H; Kono K
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):1918-20. PubMed ID: 22202238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer.
    Singh P; Toom S; Huang Y
    J Hematol Oncol; 2017 May; 10(1):105. PubMed ID: 28494772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgens and esophageal cancer: What do we know?
    Sukocheva OA; Li B; Due SL; Hussey DJ; Watson DI
    World J Gastroenterol; 2015 May; 21(20):6146-56. PubMed ID: 26034350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapies in metastatic esophageal cancer: advances over the past decade.
    Mohamed A; El-Rayes B; Khuri FR; Saba NF
    Crit Rev Oncol Hematol; 2014 Aug; 91(2):186-96. PubMed ID: 24582516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on metastatic gastric and esophageal cancers.
    Shah MA
    J Clin Oncol; 2015 Jun; 33(16):1760-9. PubMed ID: 25918288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Report on the FDA-AACR Immuno-oncology Drug Development Workshop.
    Curran C; Sharon E
    Cancer Immunol Res; 2017 Apr; 5(4):282-285. PubMed ID: 28373216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of immune checkpoint inhibitors].
    Kitano S
    Rinsho Ketsueki; 2017; 58(8):966-976. PubMed ID: 28883282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapeutic and targeted strategies for locally advanced and metastatic esophageal cancer.
    Forde PM; Kelly RJ
    J Thorac Oncol; 2013 Jun; 8(6):673-84. PubMed ID: 23591158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.
    Kaur A; Dasanu CA
    Expert Opin Pharmacother; 2011 Nov; 12(16):2493-503. PubMed ID: 21967344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of esophageal cancer development and progression.
    Denlinger CE; Thompson RK
    Surg Clin North Am; 2012 Oct; 92(5):1089-103. PubMed ID: 23026271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.